APC in the News
Morning Edition updates its GLP-1 story
NPR ran an updated story on the 'battle' between compounders and drug makers over GLP-1 weight-loss drugs.
December 12, 2024
Legit or not? ABC News looks at the difference
ABC News turned to APC for insight into the difference between legit GLP-1 compounders and fly-by-night 'wellness' sites.
December 4, 2024
Covering the GLP-1 shortage
Reuters did an excellent job updating the status of the Wegovy shortage.
November 25, 2024
NPR hits the GLP-1 nail on the head
National Public Radio did a spot-on job explaining the current situation with compounded GLP-1 drugs.
November 21, 2024
Not holding back
We pull no punches in this article about Novo's latest shenanigans
October 30, 2024
Video appearance: APC talks the legal issues
APC CEO Scott Brunner was a guest on "On The Pen" — a YouTube channel dedicated to all things GLP-1.
October 30, 2024
PharmExec features APC execs talking about the compounding process
From the manufacturing process to patient and provider challenges, this PharmExec video interview covers all things compounding.
October 24, 2024
APC calls out Novo in Reuters
Reuters used our comment that there's a difference between making molecules and compounding with them.
October 24, 2024
Previous news coverage
The Brits could have done better
UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs. (October 23, 2024)
Video: APC on Scripps
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide. (October 18, 2024)
Tirzepatide fallout in The Hill
The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision. (October 11, 2024)
Echoing our position
Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As. (October 10, 2024)
Wired story isn’t perfect, but…
This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues. (October 10, 2024)
Wired focuses on GLP-1 patient fallout
Wired looks at how some patients are being hit hard by tirzepatide coming off shortage. (October 9, 2024)
Quartz mentions APC
Not a big deal, but it shows we're getting media coverage across the spectrum. (October 9, 2024)
San Diego news radio focuses on GLP-1 price
It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻 (October 9, 2024)
CNN gets it spot on
The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage. (October 9, 2024)
Medscape focuses on compounders
Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective. (October 7, 2024)
Commenting on the tirzepatide announcement
Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective. (October 4, 2024)
Talking about those legal threats
Baseless but time-consuming lawsuit threats make compounders shy. (September 27, 2024)
APC does its best in a Hill article
The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott. (September 27, 2024)
Weighing in on Lilly’s tirzepatide vials
Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly. (September 27, 2024)
Shortage compounding is not a loophole, Scott explains to Axios
"It is absolutely intentional policy on the part of FDA." (September 27, 2024)
Scott predicts ongoing off-and-on shortages
Don't expect brand-name GLP1s to be available long-term, he says (September 25, 2024)
Tenille talks about the cost of firefighters’ lives
The California Board of Pharmacy looked to ban glutathione, but the pushback was hard. (September 24, 2024)
A quick quote from Scott in WaPo
The Washington Post's story "Eli Lilly ramps up its fight against imitation weight-loss drugs" contains a short quote from CEO Scott Brunner. (August 31, 2024)
Inside Health Policy quotes Scott (again)
In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great quote from CEO Scott Brunner. (August 28, 2024)
Scott on Lilly on GLP-1s on CBS
You’ve probably seen the news that Eli Lilly will begin selling Zepbound in vials by mail. What you may have missed is that the CBS News story quoted APC CEO Scott Brunner. (August 28, 2024)
We gave background to Inside Health Policy
Inside Health Policy used APC for information in its piece “Uncertainty Looms Over Bulk Production Of Personalized GLP-1 Drugs.” (August 28, 2024)
Inside Health Policy covers our comment
Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered in detail by Inside Health Policy. (August 28, 2024)
Masoud on ABC News
APC member Masoud Rashidi did a great job defending compounding on ABC News. (August 28, 2024)
Joe Navarra on NBC Nightly News
The story this past Monday is one of the best media reports on compounding we’ve seen. (August 27, 2024)
